Pathological autoantibodies in cardiomyopathy

References

• American Heart Association. Dallas; Heart disease and stroke statistics—2007 update. Circulation 2007; 115: e69–e171
   Web of Science ®Google Scholar
• Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, Olsen I, Thiene G, Goodwin J, Gyarfas I, et al. Report of the WHO/ISFC task force on the definition and classification of cardiomyopathies. Circulation 1996; 93: 841–842
   PubMed Web of Science ®Google Scholar
• Morita H, Seidman J, Seidman CE. Genetic causes of human heart failure. J Clin Invest 2005; 115: 518–526
   PubMed Web of Science ®Google Scholar
• Fabrizio L, Regan TJ. Alcoholic cardiomyopathy. Cardiovasc Drugs Ther 1994; 8: 89–94
   PubMed Web of Science ®Google Scholar
• Chien KR. Myocyte survival pathways and cardiomyopathy: Implications for trastuzumab cardiotoxicity. Semin Oncol 2000; 27: 9–17
   PubMed Web of Science ®Google Scholar
• MacLellan WR, Lusis AJ. Dilated cardiomyopathy: Learning to live with yourself. Nat Med 2003; 9: 1455–1456
   PubMed Web of Science ®Google Scholar
• Freedman NJ, Lefkowitz RJ. Anti-beta1-adrenergic receptor antibodies and heart failure: Causation, not just correlation. J Clin Invest 2004; 113: 1379–1382
   PubMed Web of Science ®Google Scholar
• Jahns R, Boivin V, Lohse MJ. Beta1-adrenergic receptor function, autoimmunity, and pathogenesis of dilated cardiomyopathy. Trends Cardiovasc Med 2006; 16: 20–24
   PubMed Web of Science ®Google Scholar
• Kühl U, Pauschinger M, Seeberg B, Lassner D, Noutsias M, Poller W, Schultheiss HP. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 2005; 112: 1965–1970
   PubMed Web of Science ®Google Scholar
• Limas CJ. Cardiac autoantibodies in dilated cardiomyopathy. Circulation 1997; 95: 1979–1980
   PubMed Web of Science ®Google Scholar
• Luppi P, Rudert WA, Zanone MM, Stassi G, Trucco G, Finegold D, Boyle GJ, Del Nido P, McGowan FX, Trucco M. Idiopathic dilated cardiomyopathy. A superantigen-driven autoimmune disease. Circulation 1998; 98: 777–785
   PubMed Web of Science ®Google Scholar
• Mahrholdt H, Wagner A, Deluggi CC, Kispert E, Hager S, Meinhardt G, Vogelsberg H, Fritz P, Dippon J, Bock C-T, et al. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation 2006; 114: 1581–1590
   PubMed Web of Science ®Google Scholar
• Schultheiss HP, Kühl U, Janda I, Melzner B, Ulrich G, Morad M. Antibody-mediated enhancement of calcium permeability in cardiac myocytes. J Exp Med 1988; 168: 2102–2109
   Web of Science ®Google Scholar
• Pohlner K, Portig I, Pankuweit S, Lottspeich F, Maisch B. Identification of mitochondrial antigens recognized by the antibody in sera of patients with dilated cardiomyopathy by two-dimensional gel electrophoresis and protein sequencing. Am J Cardiol 1997; 80: 1040–1045
   PubMed Web of Science ®Google Scholar
• Neumann DA, Burek CL, Baughman KL, Rose NR, Herskowitz A. Circulating heart-reactive antibodies in patients with myocarditis or cardiomyopathy. J Am Coll Cardiol 1990; 16: 839–846
   PubMedGoogle Scholar
• Caforio AL, Mahon NJ, Tona F, McKenna WJ. Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: Pathogenetic and clinical significance. Eur J Heart Fail 2002; 4: 411–417
   PubMed Web of Science ®Google Scholar
• Okazaki T, Tanaka Y, Nishio R, Mitsuiye T, Mizoguchi A, Wang J, Ishida M, Hiai H, Matsumori A, Minato N, et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 2003; 9: 1477–1483
   PubMed Web of Science ®Google Scholar
• Göser S, Andrassy M, Buss SJ, Leuschner F, Volz CH, Öttl R, Zittrich S, Blaudeck N, Hardt SE, Pfitzer G, et al. Cardiac troponin I but not cardiac troponin T induces severe autoimmune inflammation in the myocardium. Circulation 2006; 114: 1693–1702
   PubMed Web of Science ®Google Scholar
• Li Y, Heuser JS, Cunningham LC, Kosanke SD, Cunningham MW. Mimicry and antibody-mediated cell signaling in autoimmune myocarditis. J Immunol 2006; 177: 8234–8240
   PubMed Web of Science ®Google Scholar
• Magnusson Y, Wallukat G, Waagstein F, Hjalmarson Å, Hoebeke J. Autoimmunity in idiopathic dilated cardiomyopathy. Characterization of antibodies against the beta1-adrenoceptor with positive chronotropic effect. Circulation 1994; 89: 2760–2767
   PubMed Web of Science ®Google Scholar
• Jahns R, Boivin V, Siegmund C, Inselmann G, Lohse MJ, Boege F. Autoantibodies activating human beta1-adrenergic receptors are associated with reduced cardiac function in chronic heart failure. Circulation 1999; 99: 649–654
   PubMed Web of Science ®Google Scholar
• Fu LXM, Magnusson Y, Bergh CH, Waagstein F, Hjalmarson Å, Hoebeke J. Localization of a functional autoimmune epitope on the second extracellular loop of the human muscarinic acetylcholine receptor 2 in patients with idiopathic dilated cardiomyopathy. J Clin Invest 1993; 91: 1964–1968
   PubMed Web of Science ®Google Scholar
• Limas CJ. Autoimmunity in dilated cardiomyopathy and the major histocompatibility complex. Int J Cardiol 1996; 54: 113–116
   PubMed Web of Science ®Google Scholar
• Limas CJ, Iakovis P, Anyfantakis A, Kroupis C, Cokkinos DV. Familial clustering of autoimmune diseases in patients with dilated cardiomyopathy. Am J Cardiol 2004; 93: 1189–1191
   PubMed Web of Science ®Google Scholar
• Caforio AL, Mahon NG, Kamran Baig M, Tona F, Murphy RT, Elliott PM, McKenna WJ. Prospective familial assessment in dilated cardiomyopathy: Cardiac autoantibodies predict disease development in asymptomatic relatives. Circulation 2007; 115: 76–83
   PubMed Web of Science ®Google Scholar
• Hoebeke J. Structural basis of autoimmunity against G protein-coupled membrane receptors. Int J Cardiol 1996; 54: 103–111
   PubMed Web of Science ®Google Scholar
• Mobini R, Maschke H, Waagstein F. New insights into the pathogenesis of dilated cardiomyopathy: Possible underlying mechanisms and therapy. Autoimmun Rev 2004; 3: 277–284
   PubMed Web of Science ®Google Scholar
• Ferrari I, Levin M, Wallukat G, Elies R, Lebesgue D, Chiale P, Elizari M, Rosenbaum M, Hoebeke J. Molecular mimicry between the immunodominant ribosomal protein PO of Trypanosoma cruzi and a functional epitope on the human beta1-adrenergic receptor. J Exp Med 1995; 182: 59–65
   PubMed Web of Science ®Google Scholar
• Smulski C, Labovsky V, Levy G, Hontebeyrie M, Hoebeke J, Levin MJ. Structural basis of the cross-reaction between an antibody to the Trypanosoma cruzi ribosomal P2beta protein and the human beta1-adrenergic receptor. FASEB J 2006; 20: 1396–1406
   PubMed Web of Science ®Google Scholar
• Magnusson Y, Hjalmarson Å, Hoebeke J. Beta1-adrenoceptor autoimmunity in cardiomyopathy. Int J Cardiol 1996; 54: 137–141
   PubMed Web of Science ®Google Scholar
• Rose NR. Infection, mimics, and autoimmune disease. J Clin Invest 2001; 107: 943–944
   PubMed Web of Science ®Google Scholar
• Eriksson U, Ricci R, Hunziker L, Kurrer MO, Oudit GY, Watts TH, Sonderegger I, Bachmaier K, Kopf M, Penninger JM. Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nat Med 2003; 9: 1484–1490
   PubMed Web of Science ®Google Scholar
• Witebsky E, Rose NR, Terplan K, Paine JR, Egan RW. Chronic thyreoiditis and auto-immunization. J Am Med Assoc 1957; 164: 1439–1447
   PubMed Web of Science ®Google Scholar
• Rose NR, Bona C. Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol Today 1993; 14: 426–430
   PubMedGoogle Scholar
• Portig I, Pankuweit S, Maisch B. Antibodies against stress proteins in sera of patients with dilated cardiomyopathy. J Mol Cell Cardiol 1997; 29: 2245–2251
   PubMed Web of Science ®Google Scholar
• Okazaki T, Honjo T. Pathogenic roles of cardiac autoantibodies in dilated cardiomyopathy. Trends Mol Med 2005; 11: 322–326
   PubMed Web of Science ®Google Scholar
• Schulze K, Witzenbichler B, Christmann C, Schultheiss HP. Disturbance of myo-cardial energy metabolism in experimental virus myocarditis by antibodies against the adenine nucleotid translocator. Cardiovasc Res 1999; 44: 91–100
   PubMed Web of Science ®Google Scholar
• Khoynezhad A. Promising aspects and caveats of studies on anti-apoptotic therapies in patients with heart failure. Eur J Heart Fail 2007; 9: 120–123
   PubMed Web of Science ®Google Scholar
• Nishimura H, Okazaki T, Tanaka Y, Natakani K, Hara M, Matsumori A, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001; 291: 319–322
   PubMed Web of Science ®Google Scholar
• Caforio AL, Grazzini M, Mann J, Keeling PJ, Botazzo G, McKenna WJ, Schiaffino S. Identification of alpha- and beta-cardiac myosin heavy chain isoforms as major autoantigens in dilated cardiomyopathy. Circulation 1992; 85: 1734–1742
   PubMed Web of Science ®Google Scholar
• Lauer B, Schannwell M, Kühl U, Strauer BE, Schultheiss HP. Antimyosin autoantibodies are associated with deterioration of systolic and diastolic left ventricular function in patients with chronic myocarditis. J Am Coll Cardiol 2001; 35: 11–18
   Web of Science ®Google Scholar
• Neu N, Ploier B, Öfner C. Cardiac myosin-induced myocarditis: Heart autoantibodies are not involved in the induction of the disease. J Immunol 1990; 145: 4094–4100
   PubMed Web of Science ®Google Scholar
• Jane-wit D, Altuntas CZ, Johnson JM, Yong S, Wickley PJ, Clark P, Wang Q, Popovic ZB, Penn MS, Damron DS, et al. Beta1-adrenergic receptor autoantibodies mediate dilated cardiomyopathy by agonistically inducing cardiomyocyte apoptosis. Circulation 2007; 116: 1–12
   Web of Science ®Google Scholar
• Lohse MJ, Engelhardt S, Eschenhagen T. What is the role of beta-adrenergic signaling in heart failure?. Circ Res 2003; 93: 896–906
   PubMed Web of Science ®Google Scholar
• Matsui S, Fu M, Shimizu M, Fukuoka T, Teraoka K, Takekoshi N, Murakami E, Hjalmarson Å. Dilated cardiomyopaty defines serum autoantibodies against G protein-coupled cardiovascular receptors. Autoimmunity 1995; 21: 85–88
   PubMed Web of Science ®Google Scholar
• Wang WZ, Zhao RR, Wu BW, Jin XH, Zuh L, Hjalmarson Å, Fu LXM. Effects of anti-peptide antibodies against human M2 muscarinic receptors on cardiac function of rats in vivo. Blood Press 1996; 3: 25–27
   Google Scholar
• Baba A, Yoshikawa T, Fukuda Y, Sugiyama T, Shimada M, Akaishi M, Tsuchimoto K, Ogawa S, Fu M. Autoantibodies against M2-muscarinic acetylcholine receptors: New upstream targets in atrial fibrillation in patients with dilated cardiomyopathy. Eur Heart J 2004; 25: 1108–1115
   PubMed Web of Science ®Google Scholar
• Iwata M, Yoshikawa T, Baba A, Anzai T, Mitamura H, Ogawa S. Autoantibodies against the second extracellular loop of beta1-adrenergic receptors predict ventricular tachycardia and sudden death in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2001; 37: 418–424
   PubMed Web of Science ®Google Scholar
• Christ T, Schindelhauer S, Wettwer E, Wallukat G, Ravens U. Interaction between autoantibodies against the beta1-adrenoceptor and isoprenaline in enhancing L-type Ca2+ current in rat ventricular myocytes. J Mol Cell Cardiol 2006; 41: 716–723
   PubMed Web of Science ®Google Scholar
• Iwata M, Yoshikawa T, Baba A, Anzai T, Nakamura I, Wainai Y, Takahashi T, Ogawa S. Autoimmunity against the second extracellular loop of beta1-adrenergic receptors induces beta-adrenergic receptor desensitization and myocardial hypertrophy in vivo. Circ Res 2001; 88: 578–586
   PubMed Web of Science ®Google Scholar
• Jahns R, Siegmund C, Jahns V, Reiländer H, Maidhof A, Müller-Esterl W, Lohse MJ, Boege F. Probing human beta1- and beta2-adrenoceptors with domain-specific fusion protein antibodies. Eur J Pharmacol 1996; 316: 111–121
   PubMed Web of Science ®Google Scholar
• Jahns R, Boivin V, Krapf T, Wallukat G, Boege F, Lohse MJ. Modulation of beta1-adrenoceptor activity by domain-specific antibodies and heart failure-associated autoantibodies. J Am Coll Cardiol 2000; 36: 1280–1287
   PubMed Web of Science ®Google Scholar
• Buvall L, Täng MS, Isic A, Andersson B, Fu M. Antibodies against the beta1-adrenergic receptor induce progressive development of cardiomyopathy. J Mol Cell Cardiol 2007; 42: 1001–1007
   PubMed Web of Science ®Google Scholar
• Buvall L, Bollano E, Chen J, Shultze W, Fu M. Phenotype of early cardiomyopathic changes induced by active immunization of rats with a synthetic peptide corresponding to the second extracellular loop of the human beta1-adrenergic receptor. Clin Exp Immunol 2005; 143: 209–215
   Web of Science ®Google Scholar
• Jahns R, Boivin V, Hein L, Triebel S, Angermann CE, Ertl G, Lohse MJ. Direct evidence for a beta1-adrenergic receptor directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest 2004; 113: 1419–1429
   PubMed Web of Science ®Google Scholar
• Engelhardt S, Hein L, Wiesmann F, Lohse MJ. Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA 1999; 96: 7059–7064
   PubMed Web of Science ®Google Scholar
• Woodiwiss AJ, Tsotetsi OJ, Sprott S, Lancaster EJ, Mela T, Chung ES, Meyer TE, Norton GR. Reduction in myocardial collagen cross-linking parallels left ventricular dilatation in rat models of systolic chamber dysfunction. Circulation 2001; 103: 155–160
   PubMed Web of Science ®Google Scholar
• Nikolaev VO, Boivin V, Störk S, Angermann CE, Ertl G, Lohse MJ, Jahns R. A novel fluorescent method for the rapid detection of functional beta1-adrenergic receptor autoantibodies in heart failure. J Am Coll Cardiol 2007; 50: 423–431
   PubMed Web of Science ®Google Scholar
• Ryu KH, Tanaka N, Dalton N, Mao L, Rockman HA, Milano CA, Ross JJ. Force-frequency relations in the failing rabbit heart and responses to adrenergic stimulation. J Card Fail 1997; 3: 27–39
   PubMedGoogle Scholar
• Mao W, Fukuoka S, Iwai C, Liu J, Sharma VK, Sheu S, Fu M, Liang C. Cardiomyocyte apoptosis in autoimmune cardiomyopathy: Mediated via endoplasmic reticulum stress and exaggerated by norepinephrine. Am J Physiol Heart Circ Physiol 2007; 293: H1636–H1646
   PubMed Web of Science ®Google Scholar
• Jahns R, Boivin V, Siegmund C, Boege F, Lohse MJ, Inselmann G. Activating beta1-adrenoceptor antibodies are not associated with cardiomyopathies secondary to valvular or hypertensive heart disease. J Am Coll Cardiol 1999; 34: 1545–1551
   PubMed Web of Science ®Google Scholar
• Störk S, Boivin V, Horf R, Hein L, Lohse MJ, Angermann CE, Jahns R. Stimulating autoantibodies directed against the cardiac beta1-adrenergic receptor predict increased mortality in idiopathic cardiomyopathy. Am Heart J 2006; 152: 697–704
   PubMed Web of Science ®Google Scholar
• Limas CJ, Goldenberg IF, Limas C. Assessment of immune modulation of beta-adrenergic pathways in human dilated cardiomyopathy: Influence of methodologic factors. Am Heart J 1992; 123: 967–970
   PubMed Web of Science ®Google Scholar
• Wallukat G, Wollenberger A, Morwinski R, Pitschner HF. Anti-beta1-adrenoceptor autoantibodies with chronotropic activity from the serum of patients with dilated cardiomyopathy: Mapping of epitopes in the first and second extracellular loops. J Mol Cell Cardiol 1995; 27: 397–406
   PubMed Web of Science ®Google Scholar
• Chiale PA, Ferrari I, Mahler E, Vallazza MA, Elizari MV, Rosenbaum MB, Levin MJ. Differential profile and biochemical effects of antiautonomic membrane receptor antibodies in ventricular arrhythmias and sinus node dysfunction. Circulation 2001; 103: 1765–1771
   PubMed Web of Science ®Google Scholar
• Hershko AY, Naparstek Y. Removal of pathogenic autoantibodies by immunoadsorption. Ann N Y Acad Sci 2005; 1051: 635–646
   PubMed Web of Science ®Google Scholar
• Wallukat G, Müller J, Hetzer R. Specific removal of beta1-adrenergic antibodies directed against cardiac proteins from patients with idiopathic dilated cardiomyopathy. N Engl J Med 2002; 347: 1806
   PubMed Web of Science ®Google Scholar
• Staudt A, Hummel A, Ruppert J, Dörr M, Trimpert C, Birkenmeier K, Krieg T, Staudt Y, Felix SB. Immunoadsorption in dilated cardiomyopathy: 6-month results from a randomized study. Am Heart J 2006; 152: 712e1–712e6
   Web of Science ®Google Scholar
• Anderton SM. Peptide-based immunotherapy of autoimmunity: A path of puzzles, paradoxes, and possibilities. Immunology 2001; 104: 367–376
   PubMed Web of Science ®Google Scholar